OGXI Up On Phase II Results, DPRX Falters On Missed Steps, LXRX Awaits Dec Data

Shares of OncoGenex Pharmaceuticals Inc. (OGXI) were up over 29% in extended trading on Tuesday, following positive survival results from a phase II trial of Apatorsen in metastatic bladder cancer.

from RTT - Biotech http://ift.tt/2eDB4hh
via IFTTT